1222. Activity of Delafloxacin When Tested against Bacterial Surveillance Isolates Collected in the US and Europe During 2014-2016 as Part of a Global Surveillance Program.
Session: Poster Abstract Session: Expanded Spectrum - New Antimicrobial Susceptibility Testing
Friday, October 6, 2017
Room: Poster Hall CD
  • IDWeek2017-delafloxacin.pdf (654.9 kB)
  • Background: Delafloxacin (DLX) is an investigational anionic fluoroquinolone with an NDA that is under US FDA review to treat acute bacterial skin and skin structure infections and is undergoing Phase 3 studies to treat community-acquired bacterial pneumonia.

    Methods: A total of 36,683 Gram-positive (GP) and -negative (GN) bacteria isolated during 2014-2016 were selected from medical centers in the US and Europe. Susceptibility testing (S) was performed by frozen-form broth microdilution methods for DLX and comparators.

    Results: DLX was very active against Staphylococcus aureus (SA, n= 9,355; MIC50/90, 0.008/0.5 mg/L) while the levofloxacin (LEV) MIC50/90 was 0.25/>4 mg/L (67.9%S ). The MIC50/90 for methicillin-resistant SA (MRSA) was 0.12/1 mg/L. For MRSA, all isolates were S to vancomycin and daptomycin (DAP), linezolid and tigecycline (TGC) S was ≥99.9%. Decreased rates of S were noted for LEV (29.8%), clindamycin (72.9%), and erythromycin (17.3/17.8%; CLSI/EUCAST). Minocycline (MIC50/90, 0.12/0.25 mg/L), ceftaroline (MIC50/90, 0.25/0.5 mg/L), DAP (MIC50/90, 0.5/0.5 mg/L), and DLX (MIC50/90, 0.015/0.5 mg/L) were the most active agents tested against coagulase-negative staphylococci. Against Streptococcus pneumoniae (SPN), the MIC50/90 for DLX (0.015/0.03 mg/L) and TGC (0.03/0.06 mg/L) were the lowest among the agents tested. The DLX MIC50/90 values did not vary among the penicillin-S, -intermediate, and -R subgroups of SPN. The MIC50/90 values for DLX against S. pyogenes and S. agalactiae were 0.015/0.03 mg/L. DLX was highly active against Haemophilus influenzae. The DLX MIC50/90 (≤0.001/0.004 mg/L) was the same for β-lactamase positive and negative H. influenzae. Against Enterobacteriaceae, 76.0% of DLX MIC values were ≤1 mg/L. Susceptibility to LEV was 80.8%, and S to ceftriaxone, ceftazidime (CAZ), and cefepime ranged from 78.5-86.3%. A total of 72.6% of Pseudomonas aeruginosa isolates exhibited DLX MIC values ≤1 mg/L, while LEV S was 73.2% and CAZ was 81.6%. The MIC50/90 for both DLX and LEV were 0.5/>4 mg/L, respectively.

    Conclusion: DLX was active against a broad range of GP and GN bacteria, including MRSA and multidrug-resistant SPN. DLX merits further study as therapy in infections in which these organisms may occur.

    Robert K. Flamm, PhD1, Dee Shortridge, Ph.D.2, Michael D. Huband, BS2, Sandra McCurdy, M.S.3 and Michael A. Pfaller, M.D.2, (1)United States Committee on Antimicrobial Susceptibility Testing, Silverton, OR, (2)JMI Laboratories, Inc., North Liberty, IA, (3)Melinta Therapeutics, Inc., New Haven, CT


    R. K. Flamm, Melinta Therapeutics: Research Contractor , Research grant

    D. Shortridge, Melinta Therapeutics: Research Contractor , Research grant

    M. D. Huband, Melinta Therapeutics: Research Contractor , Research grant

    S. McCurdy, Melinta Therapeutics: Employee , Salary

    M. A. Pfaller, Melinta Therapeutics: Research Contractor , Research grant

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.